Clover Corporation Limited (ASX:CLV): FY26 Revenue Growth and Nutrition Ingredient Developments

Aditi Sarkar

13 October 2026 04:31 PM AEDT

Clover Corporation Limited (ASX:CLV): FY26 Revenue Growth and Nutrition Ingredient Developments

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 revenue rose as demand for nutritional ingredients contributed to sales.
Net profit after tax increased across the year ended 31 July 2026.
Encapsulated nutritional powders remain central to the product portfolio.
Product innovation and changing regional demand influenced the sales mix.
Input costs, foreign exchange movements and customer requirements remain relevant operating factors.

Clover Corporation Limited (ASX:CLV) refines natural oils, produces encapsulated powders and develops functional food and infant nutrition ingredients. Its marine-derived and other nutritional lipids are used in products requiring stable, ready-to-blend formulations. For the year ended 31 July 2026, Clover reported higher sales and profit alongside product development and changes in demand across its geographic markets.

FY26 Financial Performance

Clover Corporation Limited (ASX:CLV) reported FY26 revenue from ordinary activities of $97.410 million, a 13% increase from $86.004 million in FY25. The improvement represented an increase of $11.406 million. Revenue is linked to the supply of nutritional oils and formulated ingredients rather than energy commodities, making the company distinct from conventional oil and gas businesses.

FY26 profit after tax increased to $10.458 million from $7.015 million in FY25. Basic earnings per share increased to 6.26 cents from 4.20 cents. These figures reflect the reported financial statements; they should be distinguished from net income measures affected by other comprehensive items, including foreign currency translation adjustments.

In FY26, Clover Corporation Limited (ASX:CLV) recorded raw materials, consumables and conversion costs of $62.793 million, compared with $59.830 million in FY25. Sales and marketing expenses were $6.847 million, versus $5.583 million. The company also reported a net foreign exchange loss of $1.113 million, compared with a gain of $0.710 million in FY25.

Nutrition Ingredients and Manufacturing

Clover Corporation Limited (ASX:CLV) supplies refined oils and encapsulated ingredients for infant formula and other nutritional applications. Its encapsulation approach allows certain oils to be incorporated into dry powdered products while helping manage formulation and stability challenges. The company’s activities span ingredient processing, product research and commercial supply, making product quality and customer specifications important elements of operations.

The FY26 results announcement identified new products and demand for arachidonic acid (ARA) powders as contributors to the higher-margin sales mix. Clover also reported second-half revenue of $53.3 million, compared with $44.1 million in the first half. This split illustrates the progression of sales through FY26 without assuming that the same pace will continue.

Geographic Exposure and Operating Considerations

Clover Corporation Limited (ASX:CLV) reported FY26 revenue by customer delivery destination of $52.546 million in Australia and New Zealand, $31.217 million in Europe and the Middle East, $11.188 million in Asia and $2.459 million in the Americas. The geographic mix means that differing customer purchasing patterns, shipping conditions and currency movements can affect reported outcomes.

Marine oil procurement, processing costs and formulation requirements are relevant to Clover’s operations. Changes to product standards and customer approval processes may affect order timing, while foreign exchange movements can influence results from international sales. These are operational considerations rather than predictions about future earnings.

Key Insights

Clover Corporation Limited (ASX:CLV) entered the period following its FY26 reporting with a larger revenue base and higher reported profit than in FY25. Product development, encapsulation capabilities and demand from nutrition customers underpin its operating model. Subsequent company disclosures can clarify how the sales mix, operating costs and regional customer demand develop after 31 July 2026.

FAQs

Q: What does Clover Corporation produce?

A:It refines natural oils and manufactures encapsulated nutritional ingredients for applications including infant nutrition.

Q: What revenue did Clover report for FY26?

A:Revenue from ordinary activities was $97.410 million, up 13% from FY25.

Q: How did FY26 profit after tax change?

A:Profit after tax was $10.458 million, compared with $7.015 million in FY25.

Q: Which markets contributed to FY26 revenue?

A:Customers in Australia and New Zealand, Europe and the Middle East, Asia and the Americas contributed to reported sales.

Q: What are material operating considerations?

A:Ingredient sourcing, processing costs, customer requirements and foreign exchange movements are relevant to operations.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.